Pfizer Fights Celebrex Plaintiffs' Bid To Bar Experts
Firing the latest salvo in a dispute over proposed testimony, Pfizer Inc. has opposed a bid by plaintiffs in the multidistrict product liability litigation over its anti-inflammatory drug Celebrex to bar...To view the full article, register now.
Already a subscriber? Click here to view full article